Fusion Medical Technologies, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Registration with the SEC covers a secondary offering of 1.7 mil. shares of common stock. Net proceeds will go toward commercialization of the firm's FloSeal bleeding control technology, for which a modular PMA submission is being completed this quarter (see related story, p. 10). After PMA approval, the firm plans to file a PMA supplement with recently collected patient data for its related SinuSeal hemostatic sealant used in ear, nose and throat surgery for chronic sinus obstruction and infection. Placement agent for the offering is ING Baring Furman Selz LLC
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.